Robin L. Smith - 30 Apr 2025 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role
Director
Signature
/s/ Keith A. Kucinski, attorney-in fact for Robin Smith
Issuer symbol
MTNB
Transactions as of
30 Apr 2025
Net transactions value
$0
Form type
4
Filing time
02 May 2025, 17:19:48 UTC
Previous filing
13 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Smith Robin L Director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER /s/ Keith A. Kucinski, attorney-in fact for Robin Smith 02 May 2025 0001365035

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Stock Option (right to Buy) Award $0 +11,600 $0.000000 11,600 30 Apr 2025 Common Stock 11,600 $0.5900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.